![Cancer Network](https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/005/617/normal/Screenshot_2020-10-13_at_09.14.31.png?1602576896)
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma
Cancer Network,
ABSTRACT PURPOSE. To assess the ability of circulating tumor DNA (ctDNA)-based testing to identify patients with HER2 (encoded…